Tscan therapeutics announces upcoming presentations at the 63rd american society of hematology annual meeting and exposition

Waltham, mass., nov. 04, 2021 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a biopharmaceutical company focused on the development of t-cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that two abstracts related to its lead liquid tumor candidates tsc-100 and tsc-101 have been accepted for poster presentations at the upcoming american society of hematology (ash) annual meeting and exposition, being held from december 11-14, 2021. abstracts are available on the ash website at www.hematology.org. tsc-100 and tsc-101 are tcr-t cell products directed against the minor histocompatibility antigens ha-1 and ha-2, respectively, which are found only on blood cells. tscan is developing these products to prevent relapse following hematopoietic cell transplant (hct) in myeloid leukemia. the company plans to file investigational new drug applications (inds) for both programs before the end of 2021.
TCRX Ratings Summary
TCRX Quant Ranking